Fluciclovine

Summary

Fluciclovine (CHEMBL1908917) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 133.12 Da · C5H8FNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908917
Name	Fluciclovine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10820564
ChEBI	CHEBI:176400
Molecular formula	C5H8FNO2
Molecular weight	133.12
InChIKey	NTEDWGYJNHZKQW-UHFFFAOYSA-N

SMILES: C1C(CC1(C(=O)O)N)F

IUPAC name: 1-amino-3-fluorocyclobutane-1-carboxylic acid

ChEBI definition: A member of the class of cyclobutanes that is cyclobutane which carries a carboxy, amino and fluoro groups at positions 1, 1 and 3, respectively (the 1r,3r-stereoisomer).

Parent form; salt/anhydrous children: CHEMBL254468

Patent coverage: 67 distinct patent families (142 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05722925	PHASE4	ACTIVE_NOT_RECRUITING	Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
NCT03264456	PHASE1/PHASE2	COMPLETED	Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
NCT03036943	Not specified	COMPLETED	Fluciclovine (18F) Imaging of Breast Cancer
NCT03409549	Not specified	UNKNOWN	Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).